These seven bacteria destroyed more DALYS (221.6M) than tuberculosis, malaria, and HIV/AIDS combined (170.8M).

Rise of drug-resistant superbugs could make Covid pandemic look ‘minor’, expert warns Common infections will kill millions if drug resistance through misuse of antibiotics is not curbed, says England’s ex-chief medical officer theguardian.com/global-develop…

"The current antibiotic pipeline is not sufficient to protect against increasing resistance… There have been only 10 new antibiotics or combinations approved…2017 and 2023…None…constitute a new class of antibiotics." ifpma.org/publications/f…

"Antimicrobial resistance is only getting worse yet we’re not developing new trailblazing products fast enough to combat the most dangerous and deadly bacteria” who.int/news/item/14-0…

"Antimicrobial resistance is only getting worse yet we're not developing new trailblazing products fast enough to combat the most dangerous and deadly bacteria" Antibiotic pipeline not active enough to fight deadliest bacteria, WHO says cidrap.umn.edu/antimicrobial-…

Dual-targeted RNA polymerase inhibitors: conjugates of benzoxazino- and spiro-rifamycins with Nα-aroyl-N-aryl-phenylalaninamides European Patent Application EP4387618 (Novel compounds effective against drug-resistant M. tuberculosis. From Ebright lab.) freepatentsonline.com/EP4387618A1.ht…

Most of the 36,000+ Principal Investigators on NIH extramutal research grants will be delighted--even thrilled--to see $1 billion cut from ARPA-H and used instead to support competitively reviewed extramural research grants.

"{I[n the current business environment,…companies…developing novel antimicrobials are not able to support themselves with the financial return from…commercialized products…This has led…companies that have created antibiotics…to file for bankruptcy." biospace.com/article/why-is…

Nanopore tweezers show fractional-nucleotide translocation in sequence-dependent pausing by RNA polymerase (Collaboration with lab of Jens Gundlach at University of Washington) pnas.org/doi/10.1073/pn…

"We are in a race with ever-evolving bacteria — and we are losing." "The main hurdle is financial. It costs nearly $1 billion to shepherd a new antibiotic through clinical trials...[S]uccessfully developing an antibiotic is often financially ruinous." salon.com/2024/07/12/cli…

Structural basis of long-range transcription-translation coupling biorxiv.org/content/10.110… (Collaboration between our laboratory and laboratory of Gregor Blaha. Posted 07/20/24.)

Could a Conflict-Borne Superbug Bring on Our Next Pandemic? rollingstone.com/politics/polit…

"Blood…cultures from an injured service member from Ukraine grew Acinetobacter baumannii, Klebsiella pneumoniae, Enterococcus faecium, and 3 distinct Pseudomonas aeruginosa strains." Six Extensively Drug-Resistant Bacteria in an Injured Soldier, Ukraine wwwnc.cdc.gov/eid/article/29…

"The K. pneumoniae isolate, designated MRSN 110821, was nonsusceptible to every antibiotic tested...Testing identified 24 antimicrobial resistance genes, including the carbapenemases blaNDM-1 and blaOXA-48, the RMTase armA, and the ESBL blaCTX-M-15"

Structures of transcription-translation coupling complexes at each stage of the translation cycle (Collaboration between our laboratory and the laboratories of Yue Gao, Jinzhong Lin, and Chengyaun Wang. Extensively expanded preprint. Posted 07/25/24.) biorxiv.org/content/10.110…

Structural basis of RfaH-dependent transcription-translation coupling termination (Collaboration between our laboratory and laboratories of Gregor Blaha and Chengyuan Wang.) nature.com/articles/s4159…

"According to World Bank… estimates, unchecked drug-resistance could cause annual gross domestic product losses ranging from US $1 T to $3.4 T by 2030…[L]osses could rise to $100 T by 2050 if the weak pipeline for new antibiotics continues to falter." cidrap.umn.edu/antimicrobial-…

"The pipeline of new antibiotics is insufficient to keep pace with the growing global burden of drug-resistant infections. Substantial economic challenges discourage private investment in antibiotic research and development" nature.com/articles/s4159…